Latest Influenza research Stories
In a new research article, Harvard scientists outline a variety of factors that influence vaccine production and access to those vaccines.
The need to create a new flu vaccine annually could be eliminated with a universal influenza vaccine that targets a protein common to all strains of influenza A.
SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has begun dosing volunteers in a Phase I clinical trial.
SWIFTWATER, Pa., May 10, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the U.S.
ROCKVILLE, Md., May 9, 2011 /PRNewswire/ -- Novavax, Inc.
-largest livestock vaccine manufacturing facility in Canada- BELLEVILLE, ON, April 29 /PRNewswire/ - Bioniche Life Sciences Inc.
ROCKVILLE, Md., April 5, 2011 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX) announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today.
-The Company launches the clinical development of its seasonal flu vaccine- QUEBEC CITY, March 21 /PRNewswire-FirstCall/ - Medicago Inc.
BLUE BELL, Pa., March 21, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a U.S.
ROCKVILLE, Md., Feb. 28, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today an agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to LG Life Sciences, Ltd. (LGLS).
- A transitional zone between two communities containing the characteristic species of each.